[EN] RIPK1 INHIBITORS AND METHODS OF USE [FR] INHIBITEURS DE RIPK1 ET PROCÉDÉS D'UTILISATION
摘要:
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
[EN] TRICYCLIC MODULATORS OF TNF SIGNALING<br/>[FR] MODULATEURS TRICYCLIQUES DE LA SIGNALISATION DU TNF
申请人:ABBVIE INC
公开号:WO2016168641A1
公开(公告)日:2016-10-20
The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
Photocatalytic α‐Tertiary Amine Synthesis via C−H Alkylation of Unmasked Primary Amines
作者:Alison S. H. Ryder、William B. Cunningham、George Ballantyne、Tom Mules、Anna G. Kinsella、Jacob Turner‐Dore、Catherine M. Alder、Lee J. Edwards、Blandine S. J. McKay、Matthew N. Grayson、Alexander J. Cresswell
DOI:10.1002/anie.202005294
日期:2020.8.24
transfer (HAT) catalyst, provides a directsynthesis of α‐tertiary amines, or their corresponding γ‐lactams. We anticipate that this methodology will inspire new retrosynthetic disconnections for substituted amine derivatives in organicsynthesis, and particularly for challenging α‐tertiary primaryamines.